glp 1/gip receptor agonist Targeting GLP-1, GIP & GCG in Obesity and Type 2 Diabetes Research Targeting GLP-1, GIP & GCG
Description
People are losing 15, 20 percent of their body weight
Results show broad benefits with a reduced risk of substance use and psychotic disorders, seizures, neurocognitive disorders (including Alzheimers disease and dementia), coagulation disorders, cardiometabolic disorders, infectious illnesses and several respiratory conditions
Heads of State adopted a new Political Declaration under the 2030 Agenda for Sustainable Development - to reduce premature NCD mortality by one-third by 2030
Shocking Truth: Compounded GLP-1s on Groupon pose serious health risks
Methods A retrospective study was conducted using electronic medical records from 2014 to 2019 for adults with T2D at the Valencia Clnico-Malvarrosa Department of Health (Valencia, Spain)
